Приказ основних података о документу

dc.creatorSarić-Matutinović, Marija
dc.creatorKahaly, G.J.
dc.creatorŽarković, Miloš
dc.creatorĆirić, J.
dc.creatorIgnjatović, Svetlana
dc.creatorNedeljković Beleslin, B.
dc.date.accessioned2023-04-18T09:00:49Z
dc.date.available2023-04-18T09:00:49Z
dc.date.issued2023
dc.identifier.issn0391-4097
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/4654
dc.description.abstractPurpose: Graves’ orbitopathy (GO) is a specific inflammatory disorder of the orbit characterized by a highly heterogeneous clinical phenotype. The role of thyrotropin receptor antibodies (TSH-R-Ab) has been widely researched, however there is still no evidence that these antibodies have a direct pathogenic role in this pathology. The aim of this study was to examine their relation to the individual clinical features of GO. Methods: Ninety-one consecutive patients with GO were recruited. Total antibody concentration (TSH-R binding inhibitory immunoglobulins, TBII) and their functional activity (stimulating TSH-R-Ab, TSAb) were measured using binding immunoassay and cell-based bioassay, respectively. Results: Both TSAb and TBII levels were significantly associated to the clinical parameters of GO activity. TSAb was a more sensitive serological marker compared to TBII pertaining to eyelid retraction and edema, proptosis, extra-orbital muscle disorders, diplopia, irritable eye symptoms, and photophobia. TSAb, but not TBII, was a significant predictive marker of conjunctival redness, chemosis, caruncle/plica inflammation, eye irritation, and orbital pain, (odds ratio: 3.096, p = 0.016; 5.833, p = 0.009; 6.443, p = 0.020; 3.167, p = 0.045; 2.893, p = 0.032; versus 2.187, p = 0.093; 2.775, p = 0.081; 3.824, p = 0.055; 0.952, p = 0.930; 2.226, p = 0.099, respectively). Neither TSAb nor TBII correlated with the level of proptosis (ρ = 0.259, p = 0.090, and ρ = 0.254, p = 0.104, respectively), however rising TSAb levels were strongly associated to the level of proptosis. Conclusions: TSH-R-Ab were significantly associated with GO’s phenotype. Especially TSAb, as a sensitive and predictive serological biomarker, can improve diagnosis and management of GO.
dc.publisherSpringer Science and Business Media
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175036/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200161/RS//
dc.rightsrestrictedAccess
dc.sourceJournal of Endocrinological Investigation
dc.subjectBinding immunoassay
dc.subjectCell-based bioassay
dc.subjectGraves’ orbitopathy
dc.subjectOphthalmological features
dc.subjectStimulating antibodies
dc.subjectThyrotropin receptor antibodies
dc.titleThe phenotype of Graves’ orbitopathy is associated with thyrotropin receptor antibody levels
dc.typearticle
dc.rights.licenseARR
dc.citation.rankM21~
dc.identifier.wos000963641400002
dc.identifier.doi10.1007/s40618-023-02085-5
dc.identifier.pmid37020104
dc.identifier.scopus2-s2.0-85151504022
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу